Table 3.
Significant serum metabolites identified between HCs and the IT phase
| Targeted metabolomics platform | Class | Metabolite species identified as significant between the HCs and IT phase | Trend in the IT phase |
|---|---|---|---|
| Phospholipids | |||
| Positive lipids | Phosphatidylcholines (PC) | C32:1, C32:2, C34:1, C34:3, C34:4, C36:3, C36:4, C36:6, C38:3 | Decreased |
| Phosphatidylethanolamines (PE) | C38:4 | Decreased | |
| Plasmalogens | |||
| Positive lipids | Plasmalogen phosphatidylcholines (pPC) | C34:2, C36:2, C36:3, C38:6 | Increased |
| Plasmalogen phosphatidylethanolamines (PE) | C38:5, C38:7# | Increased | |
| Lysophospholipids | |||
| Negative lipids | Lysophosphatidylcholines (LPC) | sn1: C14:0, C15:0, C16:1, C18:1, C18:2, C18:3 (ω3ω6), C20:3 (ω3ω6), C20:3 (ω9), C20:4, C22:4, C22:5 (ω6) | Decreased |
| sn2: C14:0, C16:1, C18:1, C18:2, C18:3 (ω3ω6), C20:3 (ω3ω6), C20:4 | |||
| Lysophosphatidylethanolamines (LPE) | C18:0, C18:1, C18:2#, C20:3 (ω3ω6), C20:4, C22:5# (ω3) | Decreased | |
| Plasmalogen lysophospholipids | |||
| Negative lipids | Plasmalogen lysophosphatidylcholines (pLPC) | C16:0, C16:1, C18:1, C18:2 | Increased |
| Triglycerides | |||
| Positive lipids | Triglycerides | C42:1, C44:2, C46:1, C46:2, C46:3, C48:1, C48:2, C48:3, C48:4#, C50:0, C50:1, C50:2, C50:3, C50:4, C50:5, C51:1, C51:2, C51:3, C52:1, C52:2, C54:1, C54:2, C55:2, C56:5, C58:5 | Decreased |
| Amines | |||
| Biogenic amines | Amino acids | Tryptophan# | Decreased |
| Glutathione | Glutathione | Decreased | |
| Dipeptides | γ-Glutamylglutamine | Decreased | |
| Amino acids metabolites | Kynurenine, saccharopine | Decreased | |
| Hepatic injury | 4-Hydroxyproline, pipecolic acid | Increased | |
| Glycine metabolism | Betaine#, sarcosine# | Increased | |
| Other | s-Methylcysteine | Increased | |
| Sphingomyelins | |||
| Positive lipids | Sphingomyelins (SM) | C18:1/14:0, C18:1/21:0, C18:1/23:0, C18:1/25:0, C18:1/25:1 | Decreased |
| Free fatty acids and Acyl-carnitines | |||
| Negative lipids | Free fatty acids (FFA) | C18:2, C20:2 | Increased |
| Acyl-carnitines | Acyl-carnitines | Oleylcarnitine (C18:1)#, Linoleylcarnitine (C18:2) | Increased |
| Nonanoylcarnitine (C9:0) | Decreased | ||
| Others | |||
| Positive lipids | Cholestrol esters (CE) | C18:3 | Decreased |
| Oxylipins | Oxylipins | 11-HDoHE#, 14-HDoHE#, 10-HDoHE# | Increased |
| 5-HETrE, 8,9-DiHETre,#, 12,13-DiHOME,# | Decreased | ||
The metabolites identified as significant based on t-test and fold change are divided into their different classes together with their trend. All metabolites had a q value <0.05 unless otherwise indicated
# q value >0.05